WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 200...(ttp://www.sec.gov target _new http://ww...)

Date:10/14/2008

ttp://www.sec.gov" target="_new">http://www.sec.gov . For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 10 of our 2007 Annual Report on Form 20-F. Our preliminary results of operations for the third quarter 2008 are not necessarily indicative of our operating results for any future periods. Any projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

For more information, please contact:

Debra Yu, MD

Vice President Strategy

WuXi PharmaTech (Cayman) Inc.

Tel: +1-215-218-5559

Email: ir@wuxiapptec.com

Dr. Hai Mi

Executive Director of Investor Relations and Business Planning

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-3726

Email: ir@wuxiapptec.com

Juliane Snowden

Vice President of Investor Relations

Burns McClellan

Tel: +1-212-213-0006

Email: Jsnowden@burnsmc.com

'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
2. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
3. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
4. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
5. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
6. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
7. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
8. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
9. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China